PET引导下评估与优化靶向促红细胞生成素产生性肝细胞瘤A2受体的内化型抗体药物偶联物
本研究以PET成像评估一组抗EphA2单克隆抗体及其抗体药物偶联物(ADC)的药代动力学和肿瘤递送。3种抗体对人EphA2均具高亲和力,但内化速率不同(1C1 > 3B10 > 2H7);疏水性顺序为2H7 > 1C1 > 3B10,与PET测得的体内肿瘤摄取强相关,疏水性最低的3B10肿瘤摄取最高。ADC显著降低所有3种抗体的体内摄取。
要点
- 3种抗EphA2抗体均高亲和力,内化速率1C1 > 3B10 > 2H7。
- 疏水性2H7 > 1C1 > 3B10,与PET体内肿瘤摄取强相关,3B10摄取最高。
- ADC显著降低所有3种抗体的体内摄取。
核心结论
- 抗体肿瘤摄取是受内化、疏水性和化学修饰等多参数影响的复杂过程。
- 作者认为,向抗体添加药物分子可能因疏水性增加而加快抗体清除。
- 理解抗体肿瘤递送的复杂性可能有助于改进ADC工程以实现更好的肿瘤靶向和减少副作用。
研究设计与样本
- 筛选人抗EphA2单克隆抗体文库,评估内化速率、结合亲和力、表位结合和疏水性。
- 选择识别不同表位的3种抗体1C1、3B10和2H7进一步评估。
- 通过S239C突变制备ADC,每抗体2个药物分子。
- 天然单抗和ADC偶联DFO螯合剂并89Zr放射性标记后,进行细胞摄取、内化、疏水性和体内PET成像测定。
主要发现
- 3种单抗对EphA2均具高亲和力,内化速率顺序为1C1 > 3B10 > 2H7。
- 内化速率仅是影响体外细胞摄取和体内肿瘤积聚的因素之一。
- 单抗疏水性顺序为2H7 > 1C1 > 3B10,与PET测得的体内肿瘤摄取强相关,疏水性最低的3B10肿瘤摄取最高。
- ADC显著降低所有3种单抗的体内摄取。
关键数值与推荐
- ADC通过S239C突变制备,药物分子与抗体比例为2:1。
- 单抗和ADC均偶联DFO螯合剂并用89Zr放射性标记。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The erythropoietin-producing hepatoma A2 receptor (EphA2) is a tyrosine kinase overexpressed by tumor stroma and cancer cells. A high expression level of EphA2 predicts poor prognosis, correlating with disease progression and metastasis. Therefore, EphA2 is a relevant therapeutic target for human cancer. Antibodies, selectively bound to EphA2, can induce rapid receptor phosphorylation that results in antibody internalization and degradation. This internalization mechanism has been exploited with the development of antibody-drug conjugates (ADCs) for cancer chemotherapy. In this study, we used PET imaging to study the pharmacokinetics and tumor delivery of a panel of anti-EphA2 monoclonal antibodies (mAbs) with and without drug conjugates. Methods: A library of human anti-EphA2 mAbs were screened and evaluated for EphA2 internalization rate, binding affinity, epitope binding, and hydrophobicity. We chose 3 of these antibodies, denoted as 1C1, 3B10, and 2H7, which recognize different epitopes, for further evaluation. ADCs were generated by S239C mutation to give a ratio of 2 drug molecules per antibody. Native mAbs and ADCs were characterized, after conjugation to a DFO chelator and 89Zr radiolabeling, in assays including cell uptake, internalization, hydrophobicity, and in vivo imaging using PET. Results: All 3 mAbs had high affinities for EphA2 but exhibited different internalization rates following the order of 1C1 > 3B10 > 2H7. Internalization rate is only 1 factor that affects in vitro cell uptake and in vivo tumor accumulation. Interestingly, the hydrophobicity of the mAbs, which followed the order of 2H7 > 1C1 > 3B10, had a strong correlation with in vivo tumor uptake measured by PET, with the least hydrophobic antibody, 3B10, showing the highest tumor uptake. ADC significantly reduced the in vivo uptake of all 3 mAbs. Conclusion: Tumor uptake of mAb is a complex process that is affected by multiple parameters, including internalization, hydrophobicity, and chemical modification. Our results suggest that the addition of drug molecules to mAb increases the clearance of the mAb presumably due to the increased hydrophobicity. Understanding the complexity of antibody-based tumor delivery may help improve ADC engineering for better tumor targeting and reduced side effects.
引用
- Jacobson O, Li Q, Chen H, et al. PET-Guided Evaluation and Optimization of Internalized Antibody-Drug Conjugates Targeting Erythropoietin-Producing Hepatoma A2 Receptor. J Nucl Med. 2017. PMID: 28546337. doi:10.2967/jnumed.117.192245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。